MoonLake Immunotherapeutics (MLTX) Stock Forecast, Price Target & Predictions
MLTX Stock Forecast
MoonLake Immunotherapeutics stock forecast is as follows: an average price target of $79.33 (represents a 52.97% upside from MLTX’s last price of $51.86) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
MLTX Price Target
MLTX Analyst Ratings
Buy
MoonLake Immunotherapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jul 01, 2024 | Raghuram Selvaraju | H.C. Wainwright | $100.00 | $43.97 | 127.43% | 92.83% |
Apr 02, 2024 | Richard Law | Goldman Sachs | $62.00 | $48.60 | 27.57% | 19.55% |
Aug 31, 2023 | Serge Belanger | Needham | $76.00 | $56.09 | 35.48% | 46.55% |
10
MoonLake Immunotherapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 2 |
Avg Price Target | - | - | $81.00 |
Last Closing Price | $51.86 | $51.86 | $51.86 |
Upside/Downside | -100.00% | -100.00% | 56.19% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Sep 12, 2024 | Cowen & Co. | Buy | Buy | Hold |
Sep 12, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Aug 26, 2024 | Wolfe Research | - | Peer Perform | Downgrade |
Jul 01, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Jun 24, 2024 | Oppenheimer | - | Outperform | Initialise |
Apr 02, 2024 | Goldman Sachs | - | Neutral | Initialise |
Aug 31, 2023 | Needham | - | Buy | Initialise |
Feb 14, 2023 | Cantor Fitzgerald | - | Overweight | Initialise |
Nov 11, 2022 | Jefferies | - | Buy | Initialise |
10
MoonLake Immunotherapeutics Financial Forecast
MoonLake Immunotherapeutics Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Forecast
MoonLake Immunotherapeutics EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Forecast
MoonLake Immunotherapeutics Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-42.14M | $-44.03M | $-41.51M | $-39.00M | $-37.63M | $-27.39M | $-17.41M |
High Forecast | $-42.14M | $-44.03M | $-41.51M | $-33.15M | $-27.31M | $-27.39M | $-17.41M |
Low Forecast | $-42.14M | $-44.03M | $-41.51M | $-44.85M | $-46.13M | $-27.39M | $-17.41M |
Surprise % | - | - | - | - | - | - | - |
Forecast
MoonLake Immunotherapeutics SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Forecast
MoonLake Immunotherapeutics EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-0.67 | $-0.70 | $-0.66 | $-0.62 | $-0.60 | $-0.44 | $-0.28 |
High Forecast | $-0.67 | $-0.70 | $-0.66 | $-0.53 | $-0.43 | $-0.44 | $-0.28 |
Low Forecast | $-0.67 | $-0.70 | $-0.66 | $-0.71 | $-0.73 | $-0.44 | $-0.28 |
Surprise % | - | - | - | - | - | - | - |
Forecast
MoonLake Immunotherapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
VTYX | Ventyx Biosciences | $1.73 | $33.86 | 1857.23% | Buy |
AVTE | Aerovate Therapeutics | $2.61 | $13.00 | 398.08% | Hold |
CMPX | Compass Therapeutics | $1.38 | $5.00 | 262.32% | Buy |
PLRX | Pliant Therapeutics | $12.85 | $39.71 | 209.03% | Buy |
GPCR | Structure Therapeutics | $30.10 | $92.40 | 206.98% | Buy |
ABOS | Acumen Pharmaceuticals | $2.31 | $7.00 | 203.03% | Buy |
DAWN | Day One Biopharmaceuticals | $13.34 | $38.80 | 190.85% | Buy |
ETNB | 89bio | $8.38 | $22.00 | 162.53% | Buy |
TERN | Terns Pharmaceuticals | $5.71 | $14.25 | 149.56% | Buy |
ELVN | Enliven Therapeutics | $25.41 | $39.50 | 55.45% | Buy |
MLTX | MoonLake Immunotherapeutics | $51.86 | $79.33 | 52.97% | Buy |
AKRO | Akero Therapeutics | $31.20 | $46.00 | 47.44% | Buy |
AMLX | Amylyx Pharmaceuticals | $5.19 | $6.67 | 28.52% | Buy |
NUVL | Nuvalent | $92.73 | $111.57 | 20.32% | Buy |
TVTX | Travere Therapeutics | $18.26 | $21.75 | 19.11% | Buy |
ACLX | Arcellx | $87.22 | $83.00 | -4.84% | Buy |
CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |